Piper Jaffray analyst Matt O'Brien says Merit Medical Systems' acquisition of BrightWater Medical brings a "strong" product that can scale in ConvertX. There is a "clear value proposition" for ConvertX as it is a single device that displaces the current standard of the need for multiple devices and two interventional procedures, O'Brien tells investors in a research note. He believes Merit will use its resources and distribution to produce "significant growth for years down the line." O'Brien reiterates an Overweight rating on Merit Medical with a $75 price target.